Fortress Biotech, Inc. (FBIO) Analysts See $-0.57 EPS

February 24, 2018 - By Kurt Siggers

 Fortress Biotech, Inc. (FBIO) Analysts See $ 0.57 EPS

Analysts expect Fortress Biotech, Inc. (NASDAQ:FBIO) to report $-0.57 EPS on March, 15.They anticipate $0.14 EPS change or 32.56 % from last quarter’s $-0.43 EPS. After having $-0.67 EPS previously, Fortress Biotech, Inc.’s analysts see -14.93 % EPS growth. The stock increased 5.77% or $0.22 during the last trading session, reaching $4.03. About 288,692 shares traded or 124.29% up from the average. Fortress Biotech, Inc. (NASDAQ:FBIO) has risen 52.16% since February 24, 2017 and is uptrending. It has outperformed by 35.46% the S&P500.

Fortress Biotech, Inc. (NASDAQ:FBIO) Ratings Coverage

Among 2 analysts covering Fortress Biotech (NASDAQ:FBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech had 7 analyst reports since July 11, 2017 according to SRatingsIntel. H.C. Wainwright maintained Fortress Biotech, Inc. (NASDAQ:FBIO) on Wednesday, September 27 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $11.0 target in Tuesday, December 12 report. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, August 10 report. The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) earned “Buy” rating by H.C. Wainwright on Tuesday, January 2. As per Tuesday, December 5, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, July 11.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company has market cap of $204.15 million. The firm offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It currently has negative earnings. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders.

More notable recent Fortress Biotech, Inc. (NASDAQ:FBIO) news were published by: Globenewswire.com which released: “Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop …” on March 14, 2017, also Globenewswire.com with their article: “Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 …” published on May 04, 2017, Globenewswire.com published: “Fortress Biotech Reports First Quarter 2017 Financial Results and Recent …” on May 10, 2017. More interesting news about Fortress Biotech, Inc. (NASDAQ:FBIO) were released by: Globenewswire.com and their article: “Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief …” published on July 03, 2017 as well as Marketwatch.com‘s news article titled: “Fortress Biotech Inc.” with publication date: December 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.